Abstract |
Salvage therapy for patients with mantle cell lymphoma (MCL) remains a challenge. The clinical course is characterised by increasing resistance to conventional chemotherapy and a dismal long-term outcome. On the basis of studies demonstrating synergy in vitro, eight heavily pretreated patients (median age 65 years) with advanced stage MCL were individually treated with a novel combination protocol consisting of the proteasome inhibitor bortezomib (1.5 mg/m(2); Days 1 and 4), high-dose cytarabine (750-2000 mg/m(2); Days 2 and 3) and dexamethasone (40 mg daily; Days 1-4). Rituximab (375 mg/m(2)) was added in patients not refractory to prior rituximab-containing regimens. Treatment was repeated in 3-week intervals or postponed until hematologic recovery for up to four planned cycles. Toxicity consisted mainly of Grade 3/4 hematotoxicity, which occurred in all patients. Median treatment interval was 31 days. Objective responses were observed in four (50%) of eight patients, including two complete remissions. Median progression free and overall survival were 5 and 15.5 months, respectively. The combination of bortezomib and a high-dose cytarabine-containing regimen has activity in heavily pretreated patients with relapsed or refractory MCL.
|
Authors | Oliver Weigert, Eckhart Weidmann, Rudolf Mueck, Martin Bentz, Christoph von Schilling, Robert Rohrberg, Kathleen Jentsch-Ullrich, Wolfgang Hiddemann, Martin Dreyling |
Journal | Leukemia & lymphoma
(Leuk Lymphoma)
Vol. 50
Issue 5
Pg. 716-22
(May 2009)
ISSN: 1029-2403 [Electronic] United States |
PMID | 19347767
(Publication Type: Clinical Trial, Journal Article, Multicenter Study)
|
Chemical References |
- Boronic Acids
- Pyrazines
- Cytarabine
- Bortezomib
|
Topics |
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use, toxicity)
- Boronic Acids
(administration & dosage)
- Bortezomib
- Cytarabine
(administration & dosage)
- Drug Administration Schedule
- Drug-Related Side Effects and Adverse Reactions
- Female
- Humans
- Lymphoma, Mantle-Cell
(complications, drug therapy)
- Male
- Middle Aged
- Pyrazines
(administration & dosage)
- Salvage Therapy
(adverse effects, methods)
- Survival Analysis
|